AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15541082 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetic acid (ACA)
Number of subjects: 19
Study 15541082 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium hydroxide (NaOH)
Number of subjects: 19
Study 15541082 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium lauryl sulphate (SLS) with ASC or ACA
Number of subjects: 19
Study 15541082 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium hydroxide (NaOH) with SLS
Number of subjects: 19
Study 11329230 — intervention group
Group type: EXPERIMENTAL
Intervention: Strict avoidance of hypoglycemia
Number of subjects: 10
Study 9559492 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐fluorouracil (5‐FU) (50.0 mg/ml for 5 minutes)
Number of subjects: 101
Study 9559492 — intervention group
Group type: EXPERIMENTAL
Intervention: mitomycin C (MMC) (0.5 mg/ml for 3.5 minutes)
Number of subjects: 101
Study 9559492 — intervention group
Group type: COMPARATOR
Intervention: Overall (both groups)
Number of subjects: 101
Study 7871085 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine (0.3, 0.6 mg IM)
Number of subjects: 36
Study 7871085 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (2 mg oral)
Number of subjects: 36
Study 7871085 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 7871085 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine and Lorazepam (active treatments)
Number of subjects: 36
Study 7871085 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 36
Study 3281516 — intervention group
Group type: EXPERIMENTAL
Intervention: Naftidrofuryl (400 mg, two times daily for eight weeks)
Number of subjects: 40
Study 3281516 — intervention group
Group type: COMPARATOR
Intervention: Placebo (two identical tablets daily for eight weeks)
Number of subjects: 40
Study 1851680 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrist cuff at supra-systolic pressure
Number of subjects: 11
Study 1851680 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrist cuff at supra-venous pressure
Number of subjects: 11
Study 1138025 — intervention group
Group type: EXPERIMENTAL
Intervention: L-methionine supplementation at 0.58 g/day
Number of subjects: 0
Study 1138025 — intervention group
Group type: EXPERIMENTAL
Intervention: L-methionine supplementation at 1.16 g/day
Number of subjects: 0
Study 1138025 — intervention group
Group type: EXPERIMENTAL
Intervention: DL-methionine supplementation at 0.58 g/day
Number of subjects: 0
Study 1138025 — intervention group
Group type: EXPERIMENTAL
Intervention: DL-methionine supplementation at 1.16 g/day
Number of subjects: 0
Study 1138025 — intervention group
Group type: EXPERIMENTAL
Intervention: D-methionine supplementation at 0.58 g/day
Number of subjects: 0
Study 1138025 — intervention group
Group type: EXPERIMENTAL
Intervention: D-methionine supplementation at 1.16 g/day
Number of subjects: 0
Study 1138025 — intervention group
Group type: COMPARATOR
Intervention: Unsupplemented diet (control)
Number of subjects: 0
Study 31752836 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15% Guava mouth rinse
Number of subjects: 60
Study 31752836 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% Chlorhexidine (CHX) mouth rinse
Number of subjects: 60
Study 31752836 — intervention group
Group type: COMPARATOR
Intervention: Distilled water (placebo)
Number of subjects: 60
Study 28686006 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR)
Number of subjects: 86
Study 28686006 — intervention group
Group type: COMPARATOR
Intervention: Health Education
Number of subjects: 86
Study 26011787 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexketoprofen (0.25 mg/kg)
Number of subjects: 221
Study 26011787 — intervention group
Group type: COMPARATOR
Intervention: Racemic Ketoprofen (0.5 mg/kg)
Number of subjects: 221
Study 23694974 — intervention group
Group type: EXPERIMENTAL
Intervention: Botox® at 25 U/ml
Number of subjects: 20
Study 23694974 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysport® at approximately 100 U/ml
Number of subjects: 20
Study 23694974 — intervention group
Group type: EXPERIMENTAL
Intervention: Xeomin® at 25 U/ml
Number of subjects: 20
Study 23694974 — intervention group
Group type: EXPERIMENTAL
Intervention: NeuroBloc® at 50 U/ml
Number of subjects: 20
Study 23694974 — intervention group
Group type: COMPARATOR
Intervention: Comparison of mean anhidrotic area per unit for 100 U/ml of each product
Number of subjects: 20
Study 23694974 — intervention group
Group type: COMPARATOR
Intervention: Comparison of optimal concentration for each product
Number of subjects: 20
Study 22151935 — intervention group
Group type: EXPERIMENTAL
Intervention: Topically applied creatine-containing face-care formulation for 6 weeks
Number of subjects: 43
Study 22151935 — intervention group
Group type: COMPARATOR
Intervention: Cultured human dermal fibroblasts supplemented with creatine
Number of subjects: 43
Study 19192466 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine 30 mg at bedtime for 30 days
Number of subjects: 28
Study 19192466 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated depressed patients)
Number of subjects: 28
Study 17143960 — intervention group
Group type: EXPERIMENTAL
Intervention: Splenectomy with endoscopic variceal ligation (EVL)
Number of subjects: 103
Study 17143960 — intervention group
Group type: COMPARATOR
Intervention: Hassab's operation (splenectomy with pericardial devascularization)
Number of subjects: 103
Study 15496222 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil HCl (5 mg)
Number of subjects: 25
Study 15496222 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 11211743 — intervention group
Group type: EXPERIMENTAL
Intervention: Low concentration/high volume group (LC/HV, 240 ml of total volume and 5 ml.h‐1 of infusion rate, n = 20)
Number of subjects: 40
Study 11211743 — intervention group
Group type: COMPARATOR
Intervention: High concentration/low volume group (HC/LV, 96 ml of total volume and 2 ml.h‐1 of infusion rate, n = 20)
Number of subjects: 40
Study 9951744 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous fibrin glue
Number of subjects: 14
Study 9951744 — intervention group
Group type: COMPARATOR
Intervention: Second intention healing
Number of subjects: 14
Study 7811482 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 120
Study 7811482 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoanalgesia
Number of subjects: 120
Study 7811482 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group A)
Number of subjects: 120
Study 3262029 — intervention group
Group type: EXPERIMENTAL
Intervention: Rose bengal staining
Number of subjects: 104
Study 3262029 — intervention group
Group type: EXPERIMENTAL
Intervention: Schirmer's test
Number of subjects: 104
Study 3262029 — intervention group
Group type: EXPERIMENTAL
Intervention: Marginal tear film assessment
Number of subjects: 104
Study 3262029 — intervention group
Group type: EXPERIMENTAL
Intervention: Tear break-up time assessment
Number of subjects: 104
Study 3262029 — intervention group
Group type: EXPERIMENTAL
Intervention: Slit lamp examination
Number of subjects: 104
Study 29529870 — intervention group
Group type: EXPERIMENTAL
Intervention: Task group (n=51) - task-oriented circuit gait training with caregiver
Number of subjects: 144
Study 29529870 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength group (n=45) - strength training of lower extremities while sitting and lying
Number of subjects: 144
Study 29529870 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=48) - one 90-minute educational session on stroke management
Number of subjects: 144
Study 27655568 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education about heat wave hazard prevention for 3 months
Number of subjects: 298
Study 27655568 — intervention group
Group type: COMPARATOR
Intervention: No intervention measures
Number of subjects: 298
Study 25514139 — intervention group
Group type: EXPERIMENTAL
Intervention: Patellar tendon (PT)
Number of subjects: 330
Study 25514139 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadruple-stranded hamstring tendon (HT)
Number of subjects: 330
Study 25514139 — intervention group
Group type: EXPERIMENTAL
Intervention: Double bundle using hamstring tendon (DB)
Number of subjects: 330
Study 25514139 — intervention group
Group type: COMPARATOR
Intervention: Patellar tendon (PT) vs Quadruple-stranded hamstring tendon (HT)
Number of subjects: 330
Study 25514139 — intervention group
Group type: COMPARATOR
Intervention: Patellar tendon (PT) vs Double bundle using hamstring tendon (DB)
Number of subjects: 330
Study 23633407 — intervention group
Group type: EXPERIMENTAL
Intervention: H5 DNA priming followed by MIV at intervals of 12-24 weeks
Number of subjects: 0
Study 23633407 — intervention group
Group type: EXPERIMENTAL
Intervention: H5 DNA priming followed by MIV at intervals of ≤8 weeks
Number of subjects: 0
Study 23633407 — intervention group
Group type: COMPARATOR
Intervention: MIV-MIV prime-boost interval of 24 weeks
Number of subjects: 0
Study 21118565 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 ml of green tea
Number of subjects: 14
Study 21118565 — intervention group
Group type: COMPARATOR
Intervention: water (control)
Number of subjects: 14
Study 18156534 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-fill method (water-filled NGTs)
Number of subjects: 66
Study 18156534 — intervention group
Group type: COMPARATOR
Intervention: Traditional method (control group)
Number of subjects: 66
Study 16553528 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 38
Study 16553528 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine and citalopram
Number of subjects: 38
Study 16553528 — intervention group
Group type: EXPERIMENTAL
Intervention: Shorter-acting SSRIs
Number of subjects: 38
Study 16553528 — intervention group
Group type: COMPARATOR
Intervention: Unpublished studies
Number of subjects: 38
Study 12568411 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 2016
Study 12568411 — intervention group
Group type: COMPARATOR
Intervention: No Hormone Replacement Therapy (no HRT)
Number of subjects: 2016
Study 12568411 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT (self-selected)
Number of subjects: 2016
Study 12568411 — intervention group
Group type: COMPARATOR
Intervention: No HRT (self-selected)
Number of subjects: 2016
Study 12568411 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT
Number of subjects: 2016
Study 12568411 — intervention group
Group type: COMPARATOR
Intervention: Untreated women
Number of subjects: 2016
Study 12568411 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT-treated women
Number of subjects: 2016
Study 11748515 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil administered by target‐controlled infusion (target effect‐site concentrations ranging from 0.4 to 4.5 ng/mL)
Number of subjects: 103
Study 11748515 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant medications (lorazepam, morphine‐scopolamine, clonidine, or propofol)
Number of subjects: 103
Study 9459112 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol A (standard management): three nebulized albuterol treatments administered 1 hour apart and a chest radiograph obtained within 60 minutes of extubation.
Number of subjects: 22
Study 9459112 — intervention group
Group type: COMPARATOR
Intervention: Protocol B: one nebulized albuterol treatment administered immediately after extubation.
Number of subjects: 22
Study 7840572 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-g intravenous dose of FK-037
Number of subjects: 6
Study 7840572 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-g intravenous dose of FK-037
Number of subjects: 6
Study 2463689 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (0, 25, 50, or 100 mg)
Number of subjects: 40
Study 30244369 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 710
Study 30244369 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 710
Study 28005636 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume resistance training (VOL, n = 13, 10-12RM, 1-minute rest)
Number of subjects: 26
Study 28005636 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity resistance training (INT, n = 13, 3-5RM, 3-minute rest)
Number of subjects: 26
Study 28005636 — intervention group
Group type: COMPARATOR
Intervention: Both training programs (VOL and INT)
Number of subjects: 26
Study 25370890 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutri-jelly (200-ml box as daily supplement throughout radiotherapy)
Number of subjects: 74
Study 25370890 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Nutri-jelly)
Number of subjects: 74
Study 25370890 — intervention group
Group type: EXPERIMENTAL
Intervention: Study group (Nutri-jelly)
Number of subjects: 74
Study 25628188 — intervention group
Group type: EXPERIMENTAL
Intervention: Butantan surfactant
Number of subjects: 327
Study 25628188 — intervention group
Group type: COMPARATOR
Intervention: Survanta® or Curosurf® (Control)
Number of subjects: 327
Study 22105015 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue light (LED, emission maximum: 420 nm)
Number of subjects: 40
Study 22105015 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue light (LED, emission maximum: 453 nm)
Number of subjects: 40
Study 19608429 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucocyte filtration of concentrated blood (High-Hct)
Number of subjects: 40
Study 19608429 — intervention group
Group type: COMPARATOR
Intervention: Leucocyte filtration of diluted blood (Low-Hct)
Number of subjects: 40
Study 19608429 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentrated blood (High-Hct)
Number of subjects: 40
Study 17250965 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor control exercise
Number of subjects: 240
Study 17250965 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal manipulative therapy
Number of subjects: 240
Study 17250965 — intervention group
Group type: COMPARATOR
Intervention: General exercise
Number of subjects: 240
Study 15498086 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide dose titration based on post-prandial glucose levels
Number of subjects: 193
Study 15498086 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide dose titration based on pre-prandial glucose levels
Number of subjects: 193
Study 15498086 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide dose titration based on post-prandial glucose levels in metformin-treated individuals
Number of subjects: 193
Study 15498086 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide dose titration based on pre-prandial glucose levels in metformin-treated individuals
Number of subjects: 193
Study 15498086 — intervention group
Group type: COMPARATOR
Intervention: Repaglinide dose titration
Number of subjects: 193
Study 11727073 — intervention group
Group type: EXPERIMENTAL
Intervention: MIST‐VR training (group II)
Number of subjects: 30
Study 11727073 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional training exercises (group III)
Number of subjects: 30
Study 11727073 — intervention group
Group type: COMPARATOR
Intervention: No training (group I)
Number of subjects: 30
Study 9616508 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (controls)
Number of subjects: 93
Study 9616508 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthmatic patients
Number of subjects: 93
Study 8586785 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorine covers generated by bathing hands in a solution of 2% sodium tosylchloramide for 1 min.
Number of subjects: 0
Study 8586785 — intervention group
Group type: COMPARATOR
Intervention: Dechlorinated hands (bathing in a solution of 0.5% sodium thiosulphate for 15 s).
Number of subjects: 0
Study 8586785 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorine covers (2% sodium tosylchloramide) on artificially contaminated hands (Escherichia coli).
Number of subjects: 0
Study 8586785 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorine covers (2% sodium tosylchloramide) on resident flora.
Number of subjects: 0
Study 2665205 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy plus aspirin and risk factor modifications
Number of subjects: 0
Study 2665205 — intervention group
Group type: COMPARATOR
Intervention: Aspirin plus risk factor modifications
Number of subjects: 0
Study 767390 — intervention group
Group type: EXPERIMENTAL
Intervention: Active alert hypnotic induction (riding a bicycle ergometer under load, keeping eyes open, receiving suggestions of alertness)
Number of subjects: 50
Study 767390 — intervention group
Group type: COMPARATOR
Intervention: Traditional relaxation induction (standard eye fixation and relaxation induction of the Stanford Hypnotic Susceptibility Scale, Form B)
Number of subjects: 50
Study 31153107 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirfenidone 2,403 mg/day
Number of subjects: 170
Study 31153107 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 170
Study 31153107 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Number of subjects: 170
Study 28382812 — intervention group
Group type: EXPERIMENTAL
Intervention: Wii Fit
Number of subjects: 37
Study 28382812 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetrax biofeedback
Number of subjects: 37
Study 28382812 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional weight-shifting training
Number of subjects: 37
Study 25957003 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic therapy (ET)
Number of subjects: 588
Study 25957003 — intervention group
Group type: COMPARATOR
Intervention: Portacaval shunt (PCS)
Number of subjects: 588
Study 25957003 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency transjugular intrahepatic portosystemic shunt (TIPS)
Number of subjects: 588
Study 25957003 — intervention group
Group type: COMPARATOR
Intervention: Emergency portacaval shunt (EPCS)
Number of subjects: 588
Study 25957003 — intervention group
Group type: EXPERIMENTAL
Intervention: TIPS
Number of subjects: 588
Study 25957003 — intervention group
Group type: EXPERIMENTAL
Intervention: ET
Number of subjects: 588
Study 25957003 — intervention group
Group type: COMPARATOR
Intervention: PCS
Number of subjects: 588
Study 23462902 — intervention group
Group type: EXPERIMENTAL
Intervention: Jump 1
Number of subjects: 20
Study 23462902 — intervention group
Group type: EXPERIMENTAL
Intervention: Jump 3
Number of subjects: 20
Study 23462902 — intervention group
Group type: EXPERIMENTAL
Intervention: Left leg
Number of subjects: 20
Study 23462902 — intervention group
Group type: EXPERIMENTAL
Intervention: Landing data
Number of subjects: 20
Study 21947298 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean hemoglobin A(1c) levels
Number of subjects: 1017
Study 21947298 — intervention group
Group type: EXPERIMENTAL
Intervention: History of macroalbuminuria
Number of subjects: 1017
Study 21947298 — intervention group
Group type: EXPERIMENTAL
Intervention: Myocardial scar prevalence
Number of subjects: 1017
Study 21947298 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean hemoglobin A(1c)
Number of subjects: 1017
Study 21947298 — intervention group
Group type: EXPERIMENTAL
Intervention: Macroalbuminuria
Number of subjects: 1017
Study 19623570 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1283
Study 19623570 — intervention group
Group type: EXPERIMENTAL
Intervention: Care in accordance with a locally adapted national guideline
Number of subjects: 1283
Study 19623570 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 1283
Study 18254327 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmicort
Number of subjects: 210
Study 18254327 — intervention group
Group type: COMPARATOR
Intervention: Rhinocort
Number of subjects: 210
Study 18254327 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment
Number of subjects: 210
Study 15470301 — intervention group
Group type: EXPERIMENTAL
Intervention: novel therapy that enhances endothelial function and nitric oxide bioavailability
Number of subjects: 0
Study 11146708 — intervention group
Group type: EXPERIMENTAL
Intervention: External cooling
Number of subjects: 38
Study 11146708 — intervention group
Group type: COMPARATOR
Intervention: No antipyretic treatment (Control)
Number of subjects: 38
Study 9758131 — intervention group
Group type: EXPERIMENTAL
Intervention: Bathing in marine waters contaminated with domestic sewage
Number of subjects: 0
Study 9188112 — intervention group
Group type: EXPERIMENTAL
Intervention: Fascia iliaca compartment block with adrenaline (Group A)
Number of subjects: 20
Study 9188112 — intervention group
Group type: COMPARATOR
Intervention: Fascia iliaca compartment block without adrenaline (Group P)
Number of subjects: 20
Study 1827106 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin 500 mg 12-hourly
Number of subjects: 50
Study 1827106 — intervention group
Group type: COMPARATOR
Intervention: Amoxycillin 500 mg 8-hourly
Number of subjects: 50
Study 7015934 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination regimens (aminophylline + subcutaneously administered epinephrine or inhaled isoproterenol)
Number of subjects: 89
Study 7015934 — intervention group
Group type: COMPARATOR
Intervention: Epinephrine alone
Number of subjects: 89
Study 31084563 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation treatment (RTG)
Number of subjects: 24
Study 31084563 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation treatment (LTG)
Number of subjects: 24
Study 31084563 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 24
Study 28679189 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg dapoxetine two hours before sexual relations for 3 months (Group A)
Number of subjects: 18
Study 28679189 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic rehabilitative treatment (Group B)
Number of subjects: 18
Study 28679189 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological treatment in association with dynamic rehabilitative behavioural treatment for 3 months (Group C)
Number of subjects: 18
Study 26505826 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy diet (35% animal protein, 35% soy protein, 30% other plant proteins)
Number of subjects: 68
Study 26505826 — intervention group
Group type: COMPARATOR
Intervention: Control diet (0.8‐g/kg protein, 70% animal and 30% plant proteins)
Number of subjects: 68
Study 24948345 — intervention group
Group type: EXPERIMENTAL
Intervention: PTH 1-34 delivered via pump
Number of subjects: 12
Study 24948345 — intervention group
Group type: COMPARATOR
Intervention: PTH 1-34 delivered via twice-daily injection
Number of subjects: 12
Study 22632829 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous intervention (PCI)
Number of subjects: 195